OBJECTIVE: To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with osteoarthritis. METHODS: In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects. RESULTS:Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial. CONCLUSION:Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect.
RCT Entities:
OBJECTIVE: To validate the clinical efficacy and safety of Lyprinol (a patented extract from Perna Canaliculus), a 5-LOX inhibitor in patients with osteoarthritis. METHODS: In this multicenter trial, 60 patients with symptomatic osteoarthritis of the knee and hip were included to receive Lyprinol at a dose of 2 capsules twice a day. After a 4- and 8-week treatment period, the following parameters were analyzed: visual analogue scale; Lequesne functional index; global assessment by patients; global assessment by physician; and adverse effects. RESULTS:Lyprinol treatment led to significant improvement of the signs and symptoms of osteoarthritis as determined by all efficacy measures. After a 4- and 8-week treatment period, 53% and 80% (respectively) of patients experienced significant pain relief, and improvement of joint function. There was no reported adverse effect during this clinical trial. CONCLUSION:Lyprinol was very effective and is a promising anti-inflammatory product that relieves the signs and symptoms of osteoarthritis, without adverse effect.
Authors: Anna Hielm-Björkman; Riitta-Mari Tulamo; Hanna Salonen; Marja Raekallio Journal: Evid Based Complement Alternat Med Date: 2007-10-29 Impact factor: 2.629
Authors: Maryam Abshirini; Jane Coad; Frances M Wolber; Pamela von Hurst; Matthew R Miller; Hong Sabrina Tian; Marlena C Kruger Journal: Inflammopharmacology Date: 2021-03-18 Impact factor: 4.473
Authors: Chi-Ho Lee; John Hon-Kei Lum; Curtise Kin-Cheung Ng; Janice McKay; Yoki Kwok-Chu Butt; Man-Sau Wong; Samuel Chun-Lap Lo Journal: Evid Based Complement Alternat Med Date: 2007-09-26 Impact factor: 2.629